Hydrophilic or Lipophilic Statins?
Climent, Elisenda (Universitat Autònoma de Barcelona. Departament de Medicina)
Benaiges, David (Institut Hospital del Mar d'Investigacions Mèdiques)
Pedro-Botet, Juan (Universitat Autònoma de Barcelona. Departament de Medicina)

Data:	2021
Resum:	Drugs can be classified as hydrophilic or lipophilic depending on their ability to dissolve in water or in lipid-containing media. The predominantly lipophilic statins (simvastatin, fluvastatin, pitavastatin, lovastatin and atorvastatin) can easily enter cells, whereas hydrophilic statins (rosuvastatin and pravastatin) present greater hepatoselectivity. Although the beneficial role of statins in primary and secondary cardiovascular prevention has been unequivocally confirmed, the possible superiority of one statin or other regarding their solubility profile is still not well-established. In this respect, although some previously published observational studies and clinical trials observed a superiority of lipophilic statins in cardiovascular outcomes, these results could also be explained by a greater low-density lipoprotein cholesterol reduction with this statin type. On the other hand, previous studies reported conflicting results as to the possible superiority of one statin type over the other regarding heart failure outcomes. Furthermore, adverse events with statin therapy may also be related to their solubility profile. Thus, the aim of the present review was to collect clinical evidence on possible differences in cardiovascular outcomes among statins when their solubility profile is considered, and how this may also be related to the occurrence of statin-related adverse effects.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Adverse effects ; Cardiovascular disease ; Hydrophilic ; Lipophilic ; Pleiotropic effects ; Statins
Publicat a:	Frontiers in Cardiovascular Medicine, Vol. 8 (may 2021) , ISSN 2297-055X

DOI: 10.3389/fcvm.2021.687585
PMID: 34095267

11 p, 747.4 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats